View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
July 10, 2018

Galapagos unveils PINTA trial design for IPF

Galapagos has released the PINTA Phase ll trial design that aims to investigate GLPG1205 to treat patients with idiopathic pulmonary fibrosis (IPF).

Galapagos has released the PINTA Phase ll trial design that aims to investigate GLPG1205 to treat patients with idiopathic pulmonary fibrosis (IPF).

Up to 60 IPF patients are expected to be enrolled in the randomised, double-blind, placebo-controlled trial.

As part of the trial, a 100mg once-daily oral dose of GLPG1205 or placebo will be provided to the subjects for a period of 26 weeks.

Patients can choose to remain on their local standard of care as background therapy.

PINTA’s primary objective is to evaluate the change from baseline in forced vital capacity (FVC) over 26 weeks compared to placebo.

Its secondary measures comprise safety, tolerability, pharmacokinetics and pharmacodynamics, time to major events, changes in functional exercise capacity, and quality of life.

“GLPG1205 has shown signs of good activity in relevant animal models, and GPR84 has already been validated as a mechanism in combination with nintedanib in IPF.”

The trial intends to measure IPF diagnosis by central reading.

In addition, it plans to enrol patients across ten countries in Europe, North Africa, and the Middle East, and expects to dose the first patient by the second half of this year.

Galapagos chief scientific officer Dr Piet Wigerinck said: “GLPG1205 has shown signs of good activity in relevant animal models, and GPR84 has already been validated as a mechanism in combination with nintedanib in IPF.

“We have a well-designed trial with PINTA for ‘1205 that we anticipate will give us new insights into the potential value of GPR84 inhibition as a mechanism to treat this highly fatal disease.”

IPF is a chronic, persistently progressive fibrotic disorder of the lungs that usually affects adults over the age of 40.

Around 200,000 people are currently estimated to be diagnosed with IPF in the US and Europe.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU